Develops and commercializes healthcare solutions for musculoskeletal disorders. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 32% a year over the last 4 years. Every year shown ended in profit.
The market pays 18.6× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 76% of them.
Analysts' average target sits 33% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
Clearly above the class average — a step short of the very top.
Sales are growing strongly for its sector.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
The stock trades 23% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 18% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 32% a year on average.
There is $557.2M in the vault; even if every debt were paid off, $438.6M would remain.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 48/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, GMED sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: GMED is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.